2026-01-24 - Analysis Report
**Company Overview:** Merck is a leading American multinational pharmaceutical company.

**Return Rate Comparison:**

| Ticker | Cumulative Return Rate | Divergence (max: 47.60, min: -97.20, current: -56.30) |
|--------|-------------------------|--------------------------------------------|
| MRK    | 70.14%                  | -56.30 % (Relative Divergence: 28.20%)     |
| VOO    | 126.41%                 |                                            |

The cumulative return rate of MRK is 70.14%, which is lower than that of VOO, the comparison stock (126.41%). The divergence is -56.30%.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 37.0% | 15.3% | 25.0% | 0.7  | 182.1B |
| 2017-2019  | 39.0% | 15.3% | 14.0% | 0.7  | 216.8B |
| 2018-2020  | 29.0% | 25.1% | 4.0%  | 0.7  | 195.0B |
| 2019-2021  | 0.0%  | 25.1% | -65.0%| 0.6  | 191.4B |
| 2020-2022  | 43.0% | 23.0% | 36.0% | 0.5  | 277.1B |
| 2021-2023  | 51.0% | 19.3% | 30.0% | 0.3  | 272.3B |
| 2022-2024  | 18.0% | 25.1% | -11.0%| 0.3  | 248.5B |
| 2023-2025  | -11.0% | 39.7% | -86.0%| 0.3  | 262.9B |

The company's CAGR (Compound Annual Growth Rate) has varied across different periods, with a range of 0.0% to 51.0%. The Alpha, Beta, and Market Capitalization values have also fluctuated over time.

**Recent Stock Price Fluctuations:**

| Metric            | Value |
|-------------------|-------|
| Close             | $108.18 |
| 5-day SMA         | $109.35 |
| 20-day SMA        | $108.51 |
| 60-day SMA        | $99.90  |

The 5-day and 20-day Simple Moving Averages (SMA) indicate a decrease in price, while the 60-day SMA indicates a long-term decrease.

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence:**

| Indicator    | Value  |
|--------------|--------|
| Market Risk Indicator (MRI) | 0.70   |
| RSI          | 54.82  |
| PPO          | -0.45  |
| Hybrid Signal | Buy    |
| Risk Level    | Medium (MRI 0.70) |
| Recent Relative Divergence Change | -2.40 (-) |
| 7-day Rank Change | 97 (+) |
| 7-day Dynamic Expected Return Change | 25.20 (+) |

The Market Risk Indicator (MRI) is 0.70, indicating a medium risk level. The RSI is 54.82, and the PPO is -0.45. The recent relative divergence change is -2.40, and the 7-day rank change is 97.

**Expected Return (%):**

| Value  |
|--------|
| -4.60% |

The expected return is -4.60%, indicating a potential decline in value.

**Recent News & Significant Events:**

1. "Why Analysts See Merck (MRK) Differently After The Latest Price Target Reset" - Yahoo Finance
2. "Merck Stock Shares $91 Bil Success With Investors" - Trefis
3. "Merck & Co stock: Defensive giant tests investor patience as pipeline hopes fight valuation fears" - AD HOC NEWS
4. "Merck & Co., Inc. $MRK Stock Position Boosted by Joel Isaacson & Co. LLC" - MarketBeat
5. "Merck Weighs mRNA Breakthrough And Revolution Deal Against Oncology Valuation" - simplywall.st
6. "New Analyst Forecast: $MRK Given $120 Price Target" - Quiver Quantitative

**Analyst Opinions:**

|  | Key | Mean(1=StrongBuy~5=Sell) | Opinions | Target Price (avg/high/low) |
|---|-----|-------------------------|----------|-------------------------------|
| Analyst Consensus | Buy | 1.90 (~Buy) | 27 | 115.11 / 135.00 / 83.00 |

**Recent Earnings Analysis:**

| Date       | EPS | Revenue |
|------------|-----|---------|
| 2025-11-05 | 2.32 | $17.28B |
| 2025-08-05 | 1.76 | $15.81B |
| 2025-05-02 | 2.01 | $15.53B |
| 2024-11-06 | 1.25 | $16.66B |

The EPS (Earnings Per Share) has fluctuated between 1.25 and 2.32, while the revenue has ranged between $15.53B and $17.28B.

**Financial Information:**

### Revenue and Profitability:

| Quarter     | Revenue | Profit Margin |
|-------------|---------|---------------|
| 2025-09-30  | $17.28B | 77.69%        |
| 2025-06-30  | $15.81B | 77.50%        |
| 2025-03-31  | $15.53B | 77.98%        |
| 2024-12-31 | $15.62B | 75.50%        |
| 2024-09-30 | $16.66B | 75.51%        |

### Capital and Profitability:

| Quarter     | Equity     | ROE      |
|-------------|------------|----------|
| 2025-09-30   | $51.85B    | 11.16%   |
| 2025-06-30   | $48.99B    | 9.04%    |
| 2025-03-31   | $48.34B    | 10.51%   |
| 2024-12-31  | $46.31B    | 8.08%    |
| 2024-09-30  | $44.50B    | 7.09%    |

The revenue has fluctuated across different periods, with a range of $15.53B to $17.28B. The profit margin has ranged between 75.50% and 77.98%. The equity has also fluctuated across different periods, with a range of $44.50B to $51.85B. The Return on Equity (ROE) has ranged between 7.09% and 11.16%.

**Comprehensive Analysis:**

Merck is a leading American multinational pharmaceutical company with a fluctuating stock price. The company's CAGR has varied across different periods, and the Alpha, Beta, and Market Capitalization values have also fluctuated over time. The Market Risk Indicator (MRI) is 0.70, indicating a medium risk level. The RSI and PPO indicators suggest a decrease in value. The revenue has fluctuated across different periods, and the profit margin has ranged between 75.50% and 77.98%. The equity has also fluctuated across different periods, with a range of $44.50B to $51.85B. The expected return is -4.60%, indicating a potential decline in value.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.